JAMA Netw Open

Meta-analysis examines viloxazine’s efficacy in treating ADHD in youth

November 26, 2024

Study Design: This meta-analysis evaluated the efficacy of viloxazine in treating ADHD among children and adolescents. Researchers analyzed data from 5 randomized trials published between 2010 and 2024, focusing on response trajectories and temporal trends in symptom improvement.

Results: Viloxazine demonstrated superior efficacy in treating ADHD compared with placebo, with a mean difference of 5.47 points (95% CI, 4.03-6.91). The optimal dose appeared to be around 400 mg or 7 mg/kg, with diminishing returns at higher doses. Peak efficacy is typically observed within 4 to 6 weeks of treatment. Overall discontinuation rate due to adverse effects was 4.15% in the viloxazine group (45 of 1,084), with viloxazine associated with a 2.48-fold increased risk of discontinuation due to adverse effects compared with placebo.

Impact on Clinical Practice: These findings highlight viloxazine as an effective treatment option for ADHD, particularly for patients who may not tolerate stimulants. Clinicians may consider viloxazine in their treatment plans, especially for young patients seeking nonstimulant alternatives.

Source:

Yu CL, et al. (2024, November 4). JAMA Netw Open. Response Trajectories and Temporal Trends of Viloxazine Treatment for Young People With ADHD: A Meta-Analysis. https://pubmed.ncbi.nlm.nih.gov/39560942/